BMS-599626

• Description :

  BMS-599626 (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy[1][2].

• Product Name Alternative :

  AC480

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  EGFR

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bms-599626.html

• Purity :

  98.56

• Solubility :

  DMSO : 110 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1=CN2C(C(NC3=CC4=C(N(CC5=CC=CC(F)=C5)N=C4)C=C3)=NC=N2)=C1C)OC[C@H]6NCCOC6

• Molecular Formula :

  C27H27FN8O3

• Molecular Weight :

  530.55

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Wong TW, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res. 2006 Oct 15;12 (20 Pt 1) :6186-93.|[2]Torres MA, et al. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29 (4) :554-61.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Citation 01 :

  BMC Pulm Med. 2023 May 11;23 (1) :162.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Life Sci. 2021 Dec 16;289:120231.

• CAS Number :

  [714971-09-2]